'Confused' panel declares CVOTs unnecessary for OIC drugs
This article was originally published in Scrip
Chaos ruled the day at an FDA advisory committee meeting on 12 June, with some of the outside experts declaring they were confused by the agency's questions, leading to the panel reversing course – an action that in the end was a win for Salix's and Progenics' Relistor (methylnaltrexone), AstraZeneca's and Nektar's Movantik (naloxegol), Theravance's TD1211 and Develco's naloxone.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.